Clinical Trials
39 trialsSTARBURST
Telix Pharmaceuticals (Innovations) Pty Limited
Delayed Initiation of Olaparib Maintenance Therapy in Platinum Sensitive Recurrent Ovarian Cancer
University of Pittsburgh
Pembrolizumab, Paclitaxel, and Carboplatin in Patients With Advanced Stage Epithelial Ovarian Cancer (EOC).
University of Miami
A Study to Evaluate Rucaparib in Combination With Nivolumab in Patients With Selected Solid Tumors (ARIES)
pharmaand GmbH
Vaccine Therapy, Paclitaxel, and Carboplatin in Treating Patients Who Are Undergoing Surgery for Stage III or Stage IV Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer
University of Virginia
Study of Pembrolizumab With or Without CC-486 in Patients With Platinum-resistant Ovarian Cancer
Translational Research in Oncology
An Open Label Extension Study of the Efficacy of MORAb-003
Morphotek
Clinical Study of Apatinib in the Treatment of Platinum Resistant Recurrent Ovarian Cancer
First Affiliated Hospital of Harbin Medical University
Deferasirox for Treating Patients Who Have Undergone Allogeneic Stem Cell Transplant and Have Iron Overload
City of Hope Medical Center
Topotecan in Treating Patients With Recurrent Ovarian Epithelial or Primary Peritoneal Cancer
GOG Foundation
A Trial of Intravenous Denileukin Diftitox Plus Subcutaneous Pegylated IFNα-2A in Stage III or IV Ovarian Cancer
The University of Texas Health Science Center at San Antonio
AMG 706 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
GOG Foundation
A Phase II Study of Interaction of Lovastatin and Paclitaxel For Patients With Refractory or Relapsed Ovarian Cancer
University of Iowa
Carboplatin, Paclitaxel, and Surgery in Treating Patients With Advanced Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer
Masonic Cancer Center, University of Minnesota
Antithymocyte Globulin, Clofarabine, and Rituximab in Treating Patients After an Unsuccessful Stem Cell Transplant
Masonic Cancer Center, University of Minnesota
Allogeneic Natural Killer Cells in Patients With Recurrent Ovarian Cancer, Fallopian Tube, and Primary Peritoneal Cancer
Masonic Cancer Center, University of Minnesota
Antineoplaston Therapy in Treating Patients With Stage III or Stage IV Ovarian Cancer
Burzynski Research Institute
Docetaxel and Capecitabine in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cavity Cancer
Wake Forest University Health Sciences
Birinapant for Advanced Ovarian, Fallopian Tube, and Peritoneal Cancer
National Institutes of Health Clinical Center (CC)
CANVAS
Prima BioMed Ltd
Efficacy of DCVAC/OvCa Plus Standard of Care in Relapsed Platinum Resistant Epithelial Ovarian Carcinoma
Sotio Biotech Inc.
Sorafenib in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer in at Least the Second Remission
Memorial Sloan Kettering Cancer Center
Oxaliplatin and Topotecan in Advance Ovarian Cancer
National Cancer Institute (NCI)
SJG-136 in Treating Patients With Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer That Did Not Respond to Previous Treatment With Cisplatin or Carboplatin
National Cancer Institute (NCI)
S0025 Irinotecan in Treating Patients With Refractory Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer
SWOG Cancer Research Network
Carboplatin With or Without Decitabine in Treating Patients With Progressive, Advanced Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
National Cancer Institute (NCI)
Paclitaxel and Celecoxib in Treating Patients With Recurrent or Persistent Platinum-Resistant Ovarian Epithelial or Primary Peritoneal Cancer
GOG Foundation
Etoposide in Treating Patients With Advanced Ovarian or Cervical Cancer
GOG Foundation
Bevacizumab Plus Gemcitabine, Docetaxel, Melphalan, and Carboplatin in Ovarian Cancer Patients
M.D. Anderson Cancer Center
Vaccine Therapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer
GOG Foundation
Amifostine in Treating Women With Ovarian, Peritoneal, Cervical, Fallopian Tube, Uterine, or Endometrial Cancer
GOG Foundation
Docetaxel in Treating Patients With Recurrent or Refractory Ovarian or Primary Peritoneal Cancer
GOG Foundation
Capecitabine in Treating Patients With Recurrent Ovarian Epithelial or Primary Peritoneal Cavity Cancer
GOG Foundation
Paclitaxel in Treating Patients With Ovarian Epithelial Cancer or Primary Peritoneal Cancer
GOG Foundation
Depsipeptide (Romidepsin) in Treating Patients With Recurrent Ovarian Epithelial or Peritoneal Cavity Cancer
National Cancer Institute (NCI)
A Phase 2, Single-Arm Study of Volociximab Monotherapy in Subjects With Platinum-Resistant Advanced Epithelial Ovarian Cancer or Primary Peritoneal Cancer
Facet Biotech
Rebeccamycin Analogue in Treating Patients With Refractory Stage III or Stage IV Ovarian Epithelial Cancer
Northwestern University
Ph II Atrasentan + DOXIL in Recurrent Ovarian/Fallopian/Peritoneal Serous Papillary Adenocarcinoma
Vanderbilt-Ingram Cancer Center
Multicenter Clinical Trial of Intravenous OvaRex MAb-B43.13 as Post-Chemotherapy Consolidation for Ovarian Carcinoma
Unither Pharmaceuticals